# Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers

> **NCT04196465** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Asan Medical Center** · enrollment: 48 (estimated)

## Conditions studied

- Subjects With Resectable and Localized Gastric Cancer
- Subjects With Resectable Esophageal Cancer or Liver Cancer
- Subjects With Resectable Liver Cancer

## Interventions

- **DRUG:** IMC-001

## Key facts

- **NCT ID:** NCT04196465
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-09
- **Primary completion:** 2026-09-09
- **Final completion:** 2026-09-26
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04196465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04196465, "Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04196465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*